XtalPi Secures Nearly $6 Billion Outbound Licensing Deal with DoveTree

Aug 05, 2025 21:20 CST Updated 21:20

XtalPi

Computation-Driven Innovative Drug R&D Provider

DoveTree

Innovative Biopharmaceutical Manufacturer

August 5, 2025XtalPiWith DoveTree(A company established by Gregory Verdine, a legendary entrepreneur and investor in the U.S. pharmaceutical industry)XtalPi and DoveTree LLC have reached a collaboration to utilize the former's "AI + robotics" end-to-end AI-driven drug discovery platform for the discovery and development of small molecule and antibody candidate drugs targeting multiple key areas selected by the latter, primarily in oncology, autoimmune diseases, CNS, and metabolism.

Currently, XtalPiHave received the final agreement as stipulatedAn upfront payment of $51 million.Subject to the terms of the final agreement, XtalPiEntitled to receive a further payment of $49 million,And is eligible to receive an amount up to$5.89 billionPotential regulatory and commercial milestone payments, as well as potential single-digit percentage royalties based on the product's annual net sales.

In fact, as early as June 23, 2025,XtalPiSigned a multi-billion-dollar pipeline licensing letter of intent with DoveTree. Based on the upfront payment amount, this transaction should be a follow-up to that deal.

Image Source: Company Official Website Logo

Q2 Loss of $800 Million, 10% Layoffs, CEO Rejects Merger and Acquisition Deal

2025-08-04

Patient Dies! Setback for Universal CAR-T Pioneer

2025-08-04

Xenopoint Bio's DLL3 CAR-T Accepted by CDE, China Leads in DLL3 R&D Quantity

2025-08-04

Copyright Statement/Disclaimer
This article is an original piece.
This article is for informational exchange purposes only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by Yaotimes, sourced from the WeChat public image library, taken from the company's official website or the Internet, or used in accordance with the CC0 protocol. The copyright belongs to the respective owners, and Yaotimes makes every effort to credit the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
Click here to view more highlights!